Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00570193 | Photodynamic and Pharmacologic Treatment of CNV | PHASE1 | COMPLETED | 41 | — | — | Dec 1, 2006 | Jun 1, 2011 | Jul 10, 2012 | - | — |
| Arm | Type | Description |
|---|---|---|
| I | EXPERIMENTAL | Combined treatment with verteporfin (Visudyne) and ranibizumab (Lucentis) |
| II | EXPERIMENTAL | Treatment with ranibizumab (Lucentis) |
| Name | Type | Description |
|---|---|---|
| verteporfin (Visudyne) | DRUG | Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1 |
| ranibizumab (Lucentis) | DRUG | ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33\&37 per study protocol |
Inclusion Criteria: * All previously untreated CNV secondary to MD